Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 60 to 85 years on the day of inclusion~* Informed consent form signed~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Systemic hypersensitivity to egg proteins, chick proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances~* Febrile illness (oral temperature \>= 37.5°C equivalent rectal temperature \>= 38.0°C) on the day of inclusion~* Any vaccination or participation in another clinical trial in the four weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months, or long-term systemic corticosteroids therapy~* Chronic illness at a stage that could interfere with trial conduct or completion~* Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures~* Blood or blood-derived products received in the past three months~* Vaccination planned in the four weeks following the first trial vaccination~* Previous vaccination against influenza (in the previous six months) with the trial vaccine or another vaccine~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).